Daptomycin versus glycopeptides for the treatment of Enterococcus faecium bacteraemia: a cohort study
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Echeverría Esnal, Daniel
- dc.contributor.author Sorli Redó, M. Luisa
- dc.contributor.author Prim, Núria
- dc.contributor.author Martín-Ontiyuelo, Clara
- dc.contributor.author Horcajada Gallego, Juan Pablo
- dc.contributor.author Grau Cerrato, Santiago
- dc.date.accessioned 2021-12-21T06:52:30Z
- dc.date.available 2021-12-21T06:52:30Z
- dc.date.issued 2021
- dc.description.abstract Background: Ampicillin resistant and glycopeptide susceptible Enterococcus faecium bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice remains unknown. Daptomycin use for the treatment of enterococcal infections has increased, despite effectiveness and safety concerns. The objective was to compare the effectiveness and safety of daptomycin and glycopeptides in the treatment of GSEF-BSI. Methods: This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006-May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay. Results: From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189-0.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053-17.660). The need for treatment discontinuation due to adverse events was similar. Conclusions: Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin.
- dc.format.mimetype application/pdf
- dc.identifier.citation Echeverría-Esnal D, Sorli L, Prim N, Martin-Ontiyuelo C, Horcajada JP, Grau S. Daptomycin versus glycopeptides for the treatment of Enterococcus faecium bacteraemia: a cohort study. Antibiotics (Basel). 2021;10(6):716. DOI: 10.3390/antibiotics10060716
- dc.identifier.doi http://dx.doi.org/10.3390/antibiotics10060716
- dc.identifier.issn 2079-6382
- dc.identifier.uri http://hdl.handle.net/10230/51900
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Antibiotics (Basel). 2021;10(6):716
- dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Enterococcus faecium
- dc.subject.keyword Bacteraemia
- dc.subject.keyword Bloodstream infection
- dc.subject.keyword Daptomycin
- dc.subject.keyword Glycopeptides
- dc.subject.keyword Vancomycin
- dc.title Daptomycin versus glycopeptides for the treatment of Enterococcus faecium bacteraemia: a cohort study
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion